Rita Mukhtar, MD

Professor of Surgery
M_Surgery

Dr. Rita Mukhtar specializes in breast surgery and general surgery for urgent conditions. For her patients with breast cancer, she offers expertise in total skin-sparing mastectomies, breast conservation, wire localization surgery (used to show the location of tissue requiring biopsy) and sentinel lymph node biopsy (used to see if cancer has spread).

Dr. Mukhtar's research program focuses on invasive lobular carcinoma, the second most common type of breast cancer. This work is funded by the American Cancer Society and the National Cancer Institute. She teaches medical students and residents, and serves as an Associate Program Director for the UCSF General Surgery Residency.

Publications

Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.

Journal of Clinical Oncology

Chandler Scott Cortina, Ruta Brazauskas, Meghan Rose Flanagan, Kathie-Ann P. Joseph, Rita Mukhtar, Olga Kantor, Kristen M. Rezak, Laura Horst Rosenberger, Sumanas Jordan, Rachel Jimenez, Katherine A. Kopkash, Tasha Hughes, Meeghan A. Lautner, Emily L. Siegel, Zahraa Alhilli, Michael Ryan Cassidy, Rachel L. McCaffrey, Marie Catherine Lee, Anna Weiss, Melinda Stolley

Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.

Journal of Clinical Oncology

Silver Alkhafaji, Mark Jesus M Magbanua, Laura van t Veer, Karthik Giridhar, Matthew P. Goetz, Rita Mukhtar, Christos Vaklavas, Anthony D. Elias, Mei Wei, Gillian L. Hirst, Hope S. Rugo, Laura Ann Huppert, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman, Jo Chien

I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).

Journal of Clinical Oncology

Mei Wei, Anthony D. Elias, Karthik Giridhar, Matthew P. Goetz, Rita Mukhtar, Christos Vaklavas, Laura van t Veer, Silver Alkhafaji, Gillian L. Hirst, Hope S. Rugo, Nan Chen, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman, Jo Chien

Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).

Journal of Clinical Oncology

Jo Chien, Peter Norwood, Rita Mukhtar, Karthik Giridhar, Matthew P. Goetz, Christos Vaklavas, Anthony D. Elias, Mei Wei, Hope S. Rugo, Nan Chen, Alexander D. Borowsky, Lamorna Brown Swigart, Rebecca Arielle Shatsky, Laura Ann Huppert, Michelle E. Melisko, Laura Esserman

Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.

Journal of Clinical Oncology

Rita Mukhtar, Katrina Dimitroff, Christina Yau, Laura van t Veer, Jo Chien, Gillian L. Hirst, Lamorna Brown Swigart, Angela DeMichele, Douglas Yee, Hope S. Rugo, Rebecca Arielle Shatsky, Claudine Isaacs, Kamran A. Ahmed, Julia C. Tchou, Henry Mark Kuerer, Chantal Reyna, Candice A. Sauder, Laura Esserman, Judy Caroline Boughey, Mark Jesus M. Magbanua

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.

NPJ breast cancer

Mukhtar RA, Gottipati S, Yau C, López-Tarruella S, Earl H, Hayward L, Hiller L, Osdoit M, van der Noordaa M, de Croze D, Hamy AS, Laé M, Reyal F, Sonke GS, Steenbruggen TG, van Seijen M, Wesseling J, Martín M, Del Monte-Millán M, Boughey JC, Goetz MP, Hoskin T, Valero V, Edge SB, Abraham JE, Bartlett JMS, Caldas C, Dunn J, Provenzano E, Sammut SJ, Thomas JS, Graham A, Hall P, Mackintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele AM, Cole K, Pusztai L, Kim MO, J van 't Veer L, Cameron D, Esserman LJ, Fraser Symmans W

Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.

Annals of surgical oncology

Switalla KM, Boughey JC, Dimitroff K, Yau C, Ladores V, Yu H, Tchou J, Golshan M, Ahrendt G, Postlewait LM, Piltin M, Reyna CR, Matsen CB, Tuttle TM, Wallace AM, Arciero CA, Lee MC, Tseng J, Son J, Rao R, Sauder C, Naik A, Howard-McNatt M, Lancaster R, Norwood P, Esserman LJ, Mukhtar RA

Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.

Journal of Clinical Oncology

Erin Frances Cobain, Lajos Pusztai, Cathy Lynne Graham, Pat W. Whitworth, Peter D. Beitsch, Cynthia R. C. Osborne, Rakhshanda Layeequr Rahman, Nathalie MCDOWELL Johnson, Adam Brufsky, Reshma L. Mahtani, VK Gadi, Kent Hoskins, Hannah M. Linden, Rita A. Mukhtar, Laura Esserman, Josien Haan, Katie Quinn, Andrea Menicucci, M. William Audeh, Joyce O'Shaughnessy

I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).

Journal of Clinical Oncology

Amy Jo Chien, Rita A. Mukhtar, Karthik Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Christos Vaklavas, Anthony D. Elias, Mei Wei, Matthew P. Goetz, Laura van 't Veer, Silver Alkhafaji, Hope S. Rugo, Nan Chen, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman

Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.

Seminars in oncology

Corso G, Fusco N, Guerini-Rocco E, Leonardi MC, Criscitiello C, Zagami P, Nicolò E, Mazzarol G, La Vecchia C, Pesapane F, Zanzottera C, Tarantino P, Petitto S, Bianchi B, Massari G, Boato A, Sibilio A, Polizzi A, Curigliano G, De Scalzi AM, Lauria F, Bonanni B, Marabelli M, Rotili A, Nicosia L, Albini A, Calvello M, Mukhtar RA, Robson ME, Sacchini V, Rennert G, Galimberti V, Veronesi P, Magnoni F

Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.

Cancer research

Rita Mukhtar, Christina Yau, Denise Wolf, Adam Brufsky, Hannah Linden, Natasha Hunter, Reshma Mahtani, Abirami Sivapiragasam, Trevor Feinstein, Fengting Yan, Ian Grady, Priscilla McAuliffe, Michaela Tsai, Joyce O'Shaughnessy, Blanche Mavromatis, Sasha Davis, Josien Haan, William Audeh, Lavanya Samraj

Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.

Annals of surgical oncology

Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, Edmiston KK, Godellas CV, Lee MC, Carr MJ, Tonneson JE, Crown A, Lancaster RB, Woriax HE, Ewing CA, Chau HS, Patterson AK, Wong JM, Alvarado MD, Yang RL, Chan TW, Sheade JB, Ahrendt GM, Larson KE, Switalla K, Tuttle TM, Tchou JC, Rao R, Tamirisa N, Singh P, Gould RE, Terando A, Sauder C, Hewitt K, Chiba A, Esserman LJ, Mukhtar RA

Breast Conservation Surgery and Mastectomy have Similar Locoregional Recurrence Following Neoadjuvant Chemotherapy: Results from 1,462 Patients on the Prospective, Randomized I-SPY2 Trial.

Annals of surgery

Mukhtar RA, Chau H, Woriax H, Piltin M, Ahrendt G, Tchou J, Yu H, Ding Q, Dugan CL, Sheade J, Crown A, Carr M, Wong J, Son J, Yang R, Chan T, Terando A, Alvarado M, Ewing C, Tonneson J, Tamirisa N, Gould R, Singh P, Godellas C, Larson K, Chiba A, Rao R, Sauder C, Postlewait L, Lee MC, Symmans WF, Esserman LJ, Boughey JC, ISPY-2 Locoregional Working Group

Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).

Cancer research

Jennifer Rosenbluth, Christopher J. Schwartz, Tam Binh Bui, Shruti Warhadpande, Pravin Phadatare, Sigal Eini, Michael Bruck, Julissa Molina-Vega, Kami Pullakhandam, Nicole Schindler, Lamorna A. Brown Swigart, Christina Yau, Gillian Hirst, Rita Mukhtar, Karthik V. Giridhar, Olufunmilayo I. Olopade, Kevin Kalinsky, Cheryl A. Ewing, Jasmine M. Wong, Michael D. Alvarado, Laura Van’t Veer, Laura J. Esserman, Jo Chien

Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.

JAMA surgery

Osdoit M, Yau C, Symmans WF, Boughey JC, Ewing CA, Balassanian R, Chen YY, Krings G, Wallace AM, Zare S, Fadare O, Lancaster R, Wei S, Godellas CV, Tang P, Tuttle TM, Klein M, Sahoo S, Hieken TJ, Carter JM, Chen B, Ahrendt G, Tchou J, Feldman M, Tousimis E, Zeck J, Jaskowiak N, Sattar H, Naik AM, Lee MC, Rosa M, Khazai L, Rendi MH, Lang JE, Lu J, Tawfik O, Asare SM, Esserman LJ, Mukhtar RA

Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can

Cancer research

A. Jo Chien, Kevin M Kalinsky, Julissa Molina-Vega, Rita Mukhtar, Karthik Giridhar, Olufunmilayo I Olopade, Amrita Basu, Smita M Asare, Paul Henderson, Gillian Hirst, Ruixiao Lu, Ella Jones, Nola Hylton, Lamorna Brown-Swigart, Laura J van 't Veer, Douglas Yee, Ingrid Mayer, Laura J Esserman

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.

NPJ breast cancer

Yee D, Isaacs C, Wolf DM, Yau C, Haluska P, Giridhar KV, Forero-Torres A, Jo Chien A, Wallace AM, Pusztai L, Albain KS, Ellis ED, Beckwith H, Haley BB, Elias AD, Boughey JC, Kemmer K, Yung RL, Pohlmann PR, Tripathy D, Clark AS, Han HS, Nanda R, Khan QJ, Edmiston KK, Petricoin EF, Stringer-Reasor E, Falkson CI, Majure M, Mukhtar RA, Helsten TL, Moulder SL, Robinson PA, Wulfkuhle JD, Brown-Swigart L, Buxton M, Clennell JL, Paoloni M, Sanil A, Berry S, Asare SM, Wilson A, Hirst GL, Singhrao R, Asare AL, Matthews JB, Hylton NM, DeMichele A, Melisko M, Perlmutter J, Rugo HS, Fraser Symmans W, Van't Veer LJ, Berry DA, Esserman LJ

Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry.

Cancer research

Jane M Wei, Paul Kim, Cheryl Ewing, Jasmine Wong, Laura J Esserman, Michael D Alvarado, Abimbola O Olusanya, Skye Stewart, Ashley Tydon, Parima Daroui, Jeffrey V Kuo, Hannah L Park, Karen T Lane, Eliza Jeong, Kelsey Brown, Ava Hosseini, Barbara A Parker, Sarah L Blair, Athena Breast Health Network Investigators, Frederick Baehner, Olivier Harismendy, Antonia Petruse, Carlie K Thompson, Helena R Chang, Alexander D Borowsky, Christina Yau, Gillian L Hirst, Richard J Bold, Rita A Mukhtar

Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL.

Cancer research

Marie Osdoit, Christina Yau, W. Fraser Symmans, Judy C. Boughey, Smita M. Asare, Ron Balassanian, Jodi M. Carter, Yunn-Yi Chen, Kimberly Cole, Laila Khazai, Molly Klein, Dina Kokh, Gregor Krings, Sunati Sahoo, Gretchen Ahrendt, Akiko Chiba, Cheryl Ewing, Constantine Godellas, Nora Jaskowiak, Brigid Killelea, Helen Krontiras, Rachael Lancaster, Julie Lang, M. Catherine Lee, Arpana Naik, Roshni Rao, Julia Tchou, Shannon Tierney, Eleni Tousimis, Tod Tuttle, Anne Wallace, Bev Parker, Laura J. Esserman, Rita A. Mukhtar

Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

NPJ breast cancer

Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, I-SPY2 Investigators

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.

NPJ breast cancer

Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ, and I-SPY 2 Investigators